Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lansen Pharma Pays $8 Million for China Rights to a Novartis Dermatology Drug

publication date: Apr 1, 2014
Lansen Pharmaceutical acquired China rights to a Novartis treatment for inflammatory skin diseases, Sicorten Plus. A synthetic corticosteroid, Sicorten Plus is already marketed in China. Larsen made an $8 million upfront payment and is liable for an additional $1.5 million in milestones, based on sales. Lansen distributes western drug products in China, specializing in rheumatic disease and dermatologic disorders. The company, which is 50.6% owned by Cathay International, was founded in 2001 and is headquartered in Ningbo, China. More details....

Stock Symbol: (HK: 503)  (NYSE: NVS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital